136 related articles for article (PubMed ID: 28012793)
21. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.
Hoeben BA; Molkenboer-Kuenen JD; Oyen WJ; Peeters WJ; Kaanders JH; Bussink J; Boerman OC
Int J Cancer; 2011 Aug; 129(4):870-8. PubMed ID: 20957635
[TBL] [Abstract][Full Text] [Related]
22. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
[TBL] [Abstract][Full Text] [Related]
23. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Yu CT; Ganul V; Roh JK; Bajetta E; O'Byrne K; de Marinis F; Eberhardt W; Goddemeier T; Emig M; Gatzemeier U;
Lancet; 2009 May; 373(9674):1525-31. PubMed ID: 19410716
[TBL] [Abstract][Full Text] [Related]
25. Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group.
Jalal S; Waterhouse D; Edelman MJ; Nattam S; Ansari R; Koneru K; Clark R; Richards A; Wu J; Yu M; Bottema B; White A; Hanna N
J Thorac Oncol; 2009 Nov; 4(11):1420-4. PubMed ID: 19701110
[TBL] [Abstract][Full Text] [Related]
26. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
27. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
Baselga J; Pfister D; Cooper MR; Cohen R; Burtness B; Bos M; D'Andrea G; Seidman A; Norton L; Gunnett K; Falcey J; Anderson V; Waksal H; Mendelsohn J
J Clin Oncol; 2000 Feb; 18(4):904-14. PubMed ID: 10673534
[TBL] [Abstract][Full Text] [Related]
28. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
29. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
[TBL] [Abstract][Full Text] [Related]
30. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R
Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
Eschmann SM; Paulsen F; Reimold M; Dittmann H; Welz S; Reischl G; Machulla HJ; Bares R
J Nucl Med; 2005 Feb; 46(2):253-60. PubMed ID: 15695784
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.
Hanna N; Lilenbaum R; Ansari R; Lynch T; Govindan R; Jänne PA; Bonomi P
J Clin Oncol; 2006 Nov; 24(33):5253-8. PubMed ID: 17114658
[TBL] [Abstract][Full Text] [Related]
33. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
34. ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with
Hegi-Johnson F; Rudd SE; Wichmann C; Akhurst T; Roselt P; Trinh J; John T; Devereux L; Donnelly PS; Hicks R; Scott AM; Steinfort D; Fox S; Blyth B; Parakh S; Hanna GG; Callahan J; Burbury K; MacManus M
BMJ Open; 2022 Nov; 12(11):e056708. PubMed ID: 36400733
[TBL] [Abstract][Full Text] [Related]
35. Phase I/IIa PET imaging study with
Joraku A; Hatano K; Kawai K; Kandori S; Kojima T; Fukumitsu N; Isobe T; Mori Y; Sakata M; Hara T; Nasu K; Minami M; Iizumi Y; Nishiyama H
Ann Nucl Med; 2019 Feb; 33(2):119-127. PubMed ID: 30406361
[TBL] [Abstract][Full Text] [Related]
36. Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study.
Meng X; Loo BW; Ma L; Murphy JD; Sun X; Yu J
J Nucl Med; 2011 Oct; 52(10):1573-9. PubMed ID: 21903741
[TBL] [Abstract][Full Text] [Related]
37. PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab.
Makris NE; Boellaard R; van Lingen A; Lammertsma AA; van Dongen GA; Verheul HM; Menke CW; Huisman MC
J Nucl Med; 2015 Feb; 56(2):249-54. PubMed ID: 25613538
[TBL] [Abstract][Full Text] [Related]
38. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
39. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
Dai D; Li XF; Wang J; Liu JJ; Zhu YJ; Zhang Y; Wang Q; Xu WG
Int J Cancer; 2016 Feb; 138(4):1003-12. PubMed ID: 26334931
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia imaging with [¹⁸F]HX4 PET in NSCLC patients: defining optimal imaging parameters.
Zegers CM; van Elmpt W; Wierts R; Reymen B; Sharifi H; Öllers MC; Hoebers F; Troost EG; Wanders R; van Baardwijk A; Brans B; Eriksson J; Windhorst B; Mottaghy FM; De Ruysscher D; Lambin P
Radiother Oncol; 2013 Oct; 109(1):58-64. PubMed ID: 24044790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]